Registry-listed formulations

quisinostat · mesh:C541788

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • Quisinostat, 12 mgRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
0%(0 trials)

Phase Distribution

Phase 1
1
20%
Phase 2
3
60%
Early Phase 1
1
20%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (20.0%)
Phase 11 (20.0%)
Phase 23 (60.0%)

Trials by Status

completed360%
active_not_recruiting120%
recruiting120%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_2

Adjuvant Quisinostat in High-Risk Uveal Melanoma

NCT06932757
active_not_recruitingearly_phase_1

Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas

NCT06824662
completedphase_2

Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

NCT02948075
completedphase_2

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

NCT01486277
completedphase_1

Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

NCT02728492

Clinical Trials (5)

Showing 5 of 5 trials
NCT06932757Phase 2

Adjuvant Quisinostat in High-Risk Uveal Melanoma

Recruiting
NCT06824662Early Phase 1

Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas

Active Not Recruiting
NCT02948075Phase 2

Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

Completed
NCT01486277Phase 2

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Completed
NCT02728492Phase 1

Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

Completed

All 5 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
5

External References

ChEMBL
CHEMBL2105763

Names & Codes

Research Codes

JNJ 26481585